Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael H Davidson

Showing results (41-50 of 300) with videos related to

Pageof 30
Sort By:
Current Cardiology Reports|October 16, 2003
Newer pharmaceutical agents to treat lipid disordersMichael H Davidson
Cleveland Clinic Journal of Medicine|July 24, 2008
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implicationsMichael H Davidson
Current Cardiology Reports|October 28, 2008
METEOR and ENHANCE: a tale of two CIMT trials: part 1Michael H Davidson
Current Cardiology Reports|October 28, 2008
METEOR and ENHANCE: a tale of two CIMT trials: part 2Michael H Davidson
The American Journal of Cardiology|December 7, 2002
Combination therapy for dyslipidemia: safety and regulatory considerationsMichael H Davidson
Nature Reviews. Cardiology|August 3, 2011
Pharmacotherapy: Implications of high-dose statin link with incident diabetesMichael H Davidson
Current Opinion in Lipidology|March 6, 2020
Reducing residual cardiovascular risk with novel therapiesMichael H Davidson
Current Cardiology Reports|October 30, 2009
AURORA and JUPITER trials: recognizing the limitations and expanding the benefits of statin treatmentMichael H Davidson
The American Journal of Cardiology|November 10, 2009
Focus on HDL as a therapeutic target for CAD risk reductionMichael H Davidson
The American Journal of Cardiology|June 14, 2008
Niacin use and cutaneous flushing: mechanisms and strategies for preventionMichael H Davidson
Pageof 30

Showing results (41-50 of 300) with videos related to

Sort By:
Pageof 30
Current Cardiology Reports|October 16, 2003
Newer pharmaceutical agents to treat lipid disordersMichael H Davidson
Cleveland Clinic Journal of Medicine|July 24, 2008
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implicationsMichael H Davidson
Current Cardiology Reports|October 28, 2008
METEOR and ENHANCE: a tale of two CIMT trials: part 1Michael H Davidson
Current Cardiology Reports|October 28, 2008
METEOR and ENHANCE: a tale of two CIMT trials: part 2Michael H Davidson
The American Journal of Cardiology|December 7, 2002
Combination therapy for dyslipidemia: safety and regulatory considerationsMichael H Davidson
Nature Reviews. Cardiology|August 3, 2011
Pharmacotherapy: Implications of high-dose statin link with incident diabetesMichael H Davidson
Current Opinion in Lipidology|March 6, 2020
Reducing residual cardiovascular risk with novel therapiesMichael H Davidson
Current Cardiology Reports|October 30, 2009
AURORA and JUPITER trials: recognizing the limitations and expanding the benefits of statin treatmentMichael H Davidson
The American Journal of Cardiology|November 10, 2009
Focus on HDL as a therapeutic target for CAD risk reductionMichael H Davidson
The American Journal of Cardiology|June 14, 2008
Niacin use and cutaneous flushing: mechanisms and strategies for preventionMichael H Davidson
Pageof 30